Flag of the European Union EU Clinical Trials Register Help

Clinical trials for DNA damage

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    101 result(s) found for: DNA damage. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2017-001647-12 Sponsor Protocol Number: ARB-001467-003 Start Date*: 2018-02-06
    Sponsor Name:Arbutus Biopharma Corporation
    Full Title: A Phase 2a, Open-Label, Study Evaluating the Safety and Anti-Viral Activity of ARB-001467 in Non-Cirrhotic, HBeAg-Negative Subjects with Chronic HBV Infection (Genotype A or B) in Combination with ...
    Medical condition: Hepatitis B virus e-antigen (HBeAg)-negative subjects with chronic hepatitis B virus infection (CHB)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10054283 HBV DNA detectable LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001995-12 Sponsor Protocol Number: CCM1006 Start Date*: 2019-09-27
    Sponsor Name:CENTRO CARDIOLOGICO SPA FONDAZIONE MONZINO
    Full Title: Cardiac Arrhythmia catheter ablation procedures guided by x-Ray imaging: N-Acetylcysteine Protection Against radiation induced Cellular damagE (CARAPACE Study).
    Medical condition: Patients with Cardiac Arrhythmia who undergo catheter ablation procedures guided by x-Ray imaging
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004849 10007518 Cardiac arrhythmia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000315-91 Sponsor Protocol Number: RG_18-236 Start Date*: 2019-09-09
    Sponsor Name:University of Birmingham
    Full Title: The pAToMiUM Trial: pilot trial of Antioxidant Therapy of Men in Unexplained Miscarriage
    Medical condition: Unexplained miscarriage and how this may relate to the quality of the sperm DNA at conception, with particular emphasis on chromatin structure and DNA fragmentation and whether this may be improved...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10065877 Dietary and nutritional therapies HLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-000597-34 Sponsor Protocol Number: CUV150 Start Date*: 2021-06-01
    Sponsor Name:CLINUVEL EUROPE LIMITED
    Full Title: A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum (XP)
    Medical condition: xeroderma pigmentosum
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001419-10 Sponsor Protocol Number: CUV152 Start Date*: 2022-01-26
    Sponsor Name:CLINUVEL EUROPE LIMITED
    Full Title: A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum C and V (XPC and XPV)
    Medical condition: Patients with Xeroderma Pigmentosum C and V
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing) FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004400-19 Sponsor Protocol Number: 1707-FIVI-084-MV Start Date*: 2019-05-30
    Sponsor Name:IVIRMA MADRID
    Full Title: Study of the effects of telomerase reactivation with Danazol on ovarian function. A Pilot Study.
    Medical condition: low ovarian reserve
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10036602 Premature ovarian failure LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000106-37 Sponsor Protocol Number: 37.07.-92906 Start Date*: 2008-08-28
    Sponsor Name:Klinik für Dermatologie und Allergologie der RUB, St. Josef Hospital
    Full Title: Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris
    Medical condition: Psoriasis vulgaris (Plaque-Typ)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004021-26 Sponsor Protocol Number: RRK 2768 Start Date*: 2005-10-06
    Sponsor Name:University Hospital Birmingham
    Full Title: Longitudinal relationship between lipodystrophy and adipocyte mitochondria DNA in HIV Patients: comparison between Efavirenz (Sustiva) plus AZT/3TC (Combivir) and a less mitochrondial DNA-toxic reg...
    Medical condition: HIV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005136-18 Sponsor Protocol Number: ARB-001467-002 Start Date*: 2016-04-13
    Sponsor Name:Arbutus Biopharma Corporation
    Full Title: A Phase 2a, Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti-Viral Activity, and Pharmacokinetics of ARB-001467 in Non-Cirrhotic, HBeAg-Negative and Positive Subjects ...
    Medical condition: Hepatitis B virus e-antigen (HBeAg)-negative and HBeAg-positive subjects with chronic Hepatitis B virus (HBV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10054283 HBV DNA detectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004055-20 Sponsor Protocol Number: ICR-CTSU/2013/10040 Start Date*: 2014-09-23
    Sponsor Name:The Royal Marsden NHS Foundation Trust [...]
    1. The Royal Marsden NHS Foundation Trust
    2. The Institute of Cancer Research
    Full Title: A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223.
    Medical condition: Castrate resistant prostate cancer with bone metastases.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005993 Bone metastases LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-001640-56 Sponsor Protocol Number: PI12/01866 Start Date*: 2014-01-31
    Sponsor Name:Fundación Para la Investigación Biomédica de Córdoba
    Full Title: Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibitio...
    Medical condition: Patients with chronic kidney disease and asymptomatic hyperuricemia on the balance of mechanisms of vascular injury and repair.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003028-19 Sponsor Protocol Number: PS_KSS_001_2019 Start Date*: 2019-10-30
    Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
    Full Title: Clinical-instrumental definition of the phenotypic spectrum, response to treatment and natural history in Pearson and Kearns-Sayre syndrome
    Medical condition: Pearson and Kearns-Sayre syndrome.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10058799 Mitochondrial encephalomyopathy PT
    20.1 10010331 - Congenital, familial and genetic disorders 10058799 Mitochondrial encephalomyopathy PT
    20.1 10010331 - Congenital, familial and genetic disorders 10051403 Mitochondrial DNA deletion PT
    20.1 10010331 - Congenital, familial and genetic disorders 10051403 Mitochondrial DNA deletion PT
    20.0 10010331 - Congenital, familial and genetic disorders 10074070 Mitochondrial encephalopathy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006032-22 Sponsor Protocol Number: 41829447 (ISRCTN No) Start Date*: 2007-04-04
    Sponsor Name:University of Manchester [...]
    1. University of Manchester
    2. Dudley Group of Hospitals NHS Trust
    Full Title: TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis
    Medical condition: Rheumatoid arthritis is associated with increased mortality from cardiovascular disease (CVD). Statins have a proven effect in reducing CVD events in at-risk populations, mostly due to their chole...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003642-20 Sponsor Protocol Number: CUV156 Start Date*: 2021-09-27
    Sponsor Name:CLINUVEL EUROPE LTD
    Full Title: A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum (XP)
    Medical condition: xeroderma pigmentosum
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000977-31 Sponsor Protocol Number: NV25361 Start Date*: 2006-05-05
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: PHASE IIIB, RANDOMIZED, OPEN LABEL STUDY OF PEGYLATED INTERFERON ALFA-2A IN COMBINATION WITH LAMIVUDINE OR ENTECAVIR COMPARED WITH UNTREATED CONTROL PATIENTS IN CHILDREN WITH HBEAG POSITIVE CHRONIC...
    Medical condition: Chronic Hepatitis B Virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10019743 Hepatitis B virus (HBV) LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004410-13 Sponsor Protocol Number: 3401 Start Date*: 2008-03-12
    Sponsor Name:Institute od Rheumatology Prague
    Full Title: A PROSPECTIVE, RANDOMISED, ASSESSOR-BLIND, MULTICENTER STUDY OF EFFICACY AND SAFETY OF COMBINED TREATMENT OF METHOTREXATE + GLUCOCORTICOIDS VERSUS GLUCOCORTICOIDS ALONE IN PATIENTS WITH POLYMYOSITI...
    Medical condition: active polymyositis, dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012503 Dermatomyositis LLT
    9.1 10036102 Polymyositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005717-36 Sponsor Protocol Number: 1645-CI-057 Start Date*: 2012-06-14
    Sponsor Name:Instituto de Investigación Sanitaria La Fe
    Full Title: Extremely low gestational age neonates randomly an assigned to be blindly resuscitated with 21% vs. 60% oxygen: influence upon mortality and chronic conditions in the neonatal period.
    Medical condition: Preterm infants aged 30 weeks or less, who need resuscitation / stabilization maneuvers with positive pressure ventilation immediately after birth
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002529-27 Sponsor Protocol Number: D5339C00001 Start Date*: 2021-02-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Modular Phase 2a Multicentre Open-Label Study to Investigate DNA-damage Response Agents (or Combinations) in Patients With Advanced Cancer Whose Tumours Contain Molecular Alterations (PLANETTE)
    Medical condition: Advanced Cancer Whose Tumours Contain Molecular Alterations
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005835-60 Sponsor Protocol Number: APHP200038 Start Date*: 2021-08-11
    Sponsor Name:Assistance Publique – Hôpitaux de Paris (AP-HP)
    Full Title: Induction therapy for lupus nephritis with no added oral corticosteroids : An open label randomised multicentre controlled trial comparing oral corticosteroids plus mycophenolate mofetil (MMF) ve...
    Medical condition: The study population will consist of Children (14 years and above) and adults (until 75 years old) with lupus nephritis ISN/RPS class III or IV (A or A/C) ± V with active lesions in at least 10% of...
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001034-35 Sponsor Protocol Number: RG_19-138 Start Date*: 2020-10-15
    Sponsor Name:University of Birmingham
    Full Title: Accelerating the Development and implementation of Personalised Treatments of DNA Damage Response agents and radiotherapy +/- immunotherapy for head and neck squamous cell cancer
    Medical condition: Head and neck squamous cell carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:52:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA